Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma

NCT01596270 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01596270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01596270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2012
Completion date
October 31, 2014
Enrollment
49 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm malignant